Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 9/20 | 0.52 |
| ▸ | MGLL | Q99685 | 13/20 | 0.47 |
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15101002 | 0.93 | ABHD6 (0.57) | ABHD6MGLLPLA2G7 | |
| Hydrochloric Acid SCHEMBL18064781 | 0.92 | ABHD6 (0.56) | ABHD6MGLLPLA2G7 | |
| SCHEMBL18785822 | 0.81 | ABHD6 (0.47) | ABHD6MGLLPLA2G7 | |
| Trifluoroacetic Acid SCHEMBL29446969 | 0.78 | MGLL (0.48) | MGLL | |
| Trifluoroacetic Acid SCHEMBL22233151 | 0.77 | PKM (0.47) | PKM | |
| SCHEMBL14834092 | 0.77 | ABHD6 (0.54) | ABHD6MGLLPLA2G7 | |
| SCHEMBL14834050 | 0.77 | ABHD6 (0.51) | ABHD6MGLLPLA2G7 | |
| SCHEMBL16935385 | 0.77 | ABHD6 (0.42) | ABHD6MGLLPKM | |
| SCHEMBL20769759 | 0.76 | MGLL (0.55) | ABHD6MGLL | |
| SCHEMBL19582363 | 0.76 | MGLL (0.52) | ABHD6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158360-A1 | Synthesis of a Monoacylglycerol Lipase Inhibitor | H. LUNDBECK A/S (DK) | 2024-05-16 | — | — | US | disclosed |
| US-11702393-B2 | Synthesis of a monoacylglycerol lipase inhibitor | H. LUNDBECK A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| EP-4139288-A1 | SYNTHESIS OF A MONOACYLGLYCEROL LIPASE INHIBITOR | H. Lundbeck A/S (DK) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214550-A1 | SYNTHESIS OF A MONOACYLGLYCEROL LIPASE INHIBITOR | H. LUNDBECK A/S (DK) | 2021-10-28 | — | — | WO | disclosed |
| US-20210323938-A1 | Synthesis of a Monoacylglycerol Lipase Inhibitor | H. LUNDBECK A/S (DK) | 2021-10-21 | — | — | US | disclosed |
| US-10463753-B2 | Radiolabeled monoacylglycerol lipase occupancy probe | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190046668-A1 | RADIOLABELED MONOACYLGLYCEROL LIPASE OCCUPANCY PROBE | H. LUNDBECK A/S (DK) | 2019-02-14 | — | — | US | disclosed |
| WO-2017143283-A1 | RADIOLABELED MONOACYLGLYCEROL LIPASE OCCUPANCY PROBE | ABIDE THERAPEUTICS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463753-B2 | Radiolabeled monoacylglycerol lipase occupancy probe | MGLL, LPL, PNLIP | ABHD6 15/4885MGLL 1/4885PLA2G7 434/4885 |
| US-20240158360-A1 | Synthesis of a Monoacylglycerol Lipase Inhibitor | MGLL, PNLIP, LPL | ABHD6 20/4885MGLL 1/4885PLA2G7 105/4885 |
| US-20190046668-A1 | RADIOLABELED MONOACYLGLYCEROL LIPASE OCCUPANCY PROBE | MGLL, LPL, PNLIP | ABHD6 15/4885MGLL 1/4885PLA2G7 434/4885 |
| US-20210323938-A1 | Synthesis of a Monoacylglycerol Lipase Inhibitor | MGLL, PNLIP, LPL | ABHD6 20/4885MGLL 1/4885PLA2G7 105/4885 |
| US-11702393-B2 | Synthesis of a monoacylglycerol lipase inhibitor | MGLL, PNLIP, LPL | ABHD6 20/4885MGLL 1/4885PLA2G7 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.